Dry powder aerosol of amphotericin b for treatment of pulmonary fungal disease

Le résumé fourni par la source

NHT101, amphotericin B (AMB) powder/DryNeb (a novel, active dry powder nebulizer), is being developed for fungal lung disease. Two studies were performed, 1) NHT101 in vitro aerosol testing, and 2) AMB efficacy-safety. AMB was micronized to ≤4 μm [D(v90)]. 1):A mesh covered chamber with AMB and 2 PTFE-magnetic bars were inserted above a motor to generate dynamic motion and AMB aerosol clouds. The latter was entrained in airflow directed to a mouthpiece driven by negative pressure approximating tidal inspiration. Aerodynamic particle sizes were 3.5-4.5/1-2μm MMAD/GSD. 2):Guinea Pigs (GP) were exposed to AMB aerosols (1mg/L; 1.67/2.84um MMAD/GSD) by nose only inhalation. Days 1, 4, and 7 were AMB exposure days. Air controls were included. GP were sacrificed on Day 8. Daily AMB average pulmonary dose was calculated at 3.76 mg/kg. For safety, 3m/3f GP were exposed to AMB and 2m/2f to air. Lungs were assayed for AMB and preserved for histopathology. For efficacy, 16m GP (8 air and 8 AMB) were challenged with a pulmonary dose of 0.67×105 aerosolized Aspergillus fumigatus (AF) conidia/kg on Day 0. Lung burden was performed Day 8. For safety, AMB caused non-adverse minimal-mild increases in lung macrophages and mixed cell inflammation. Lung AMB was ~40ug/g at sacrifice. For efficacy, of air AF GP, 1 was found dead and 2 moribund on Day 8 prior to scheduled sacrifice (survival rate of 62.5%). All AMB GP survived to necropsy. Fungal burden was higher in air GP (mean ~1000 CFU/g lung) vs AMB GP (mean ~20 CFU/g). Conclusion: NHT101 has optimal clinical aerosol characteristics. Inhaled AMB was protective in a stringent GP AF model. NHT101 possesses clinical feasibility for the treatment of fungal lung diseases.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.